Should patients pay high-cost sharing for treatments for the Hepatitis C Virus?

Treatments for the hepatitis C virus (HCV) are expensive.  At one point they cost over $80,000 per year, although costs have decreased since then.  To prevent moral hazard, should insurance companies rely on cost sharing to decrease utilization?  An article by Lakdawalla, Linthicum, and Vanderpuye-Orgle (2016) argues that they shouldn’t. Cost sharing appears even less efficient when…

Hepatitis C Around the World

The global burden of the hepatitis C virus (HCV) is distressing. “[A]n estimated 130–170 million persons (2%–3% of the world’s population) are living with hepatitis C virus (HCV) infection [1]. This infection, particularly in its chronic form, is associated with sizable morbidity and mortality. More than 350 000 deaths are attributed to HCV infection each…